Featured Research

from universities, journals, and other organizations

HIV drug that protects a fetus should be avoided for one year after childbirth, researchers say

Date:
February 28, 2010
Source:
University of Alabama at Birmingham
Summary:
A new study found that while nevirapine works well to prevent mother-to-child HIV transmission, a single dose of nevirapine in infected pregnant women can trigger resistance to some forms of the AIDS-drug cocktail (antiretrovirals). This nevirapine-induced resistance fades after about 12 months and no longer hinders the cocktail, UAB researchers say.

Women given the human immunodeficiency virus (HIV) prevention drug nevirapine to protect their fetus should not use an HIV-drug regimen that contains nevirapine for at least one year after childbirth, say researchers at the University of Alabama at Birmingham (UAB).

A new UAB study found that while nevirapine works well to prevent mother-to-child HIV transmission, a single dose of nevirapine in infected pregnant women can trigger resistance to some forms of the AIDS-drug cocktail known as combination antiretroviral treatment (ART). This nevirapine-induced resistance fades after about 12 months and no longer hinders ART, says UAB Professor of Obstetrics and Gynecology Jeffrey S.A. Stringer, M.D., the study's lead author.

The findings are published in PLoS Medicine.

Single-dose nevirapine is widely used to prevent mother-to-child transmission of HIV, an infection that affects more than 30 million people globally and leads to more than 2 million AIDS-related deaths each year.

"This study shows that women who need treatment more than 12 months after using nevirapine to prevent mother-to-child transmission safely can use standard first-line treatments in their countries," says Stringer, director of the UAB-affiliated Center for Infectious Disease Research in Zambia. "Women who need treatment sooner than that should use a combination that does not contain nevirapine, typically an ART regimen that contains protease-inhibitor drugs."

The UAB study included 878 infected women in Zambia, Cote d'Ivoire and Thailand. Some were given single-dose nevirapine and others were not; all participants were given ART immediately upon confirmed infection and monitored for one year.

Nevirapine continues to be the backbone of anti-HIV therapy in the developing world, and its usefulness in preventing mother-to-child transmission is confirmed in the new study, Stringer says.

The research is a collaboration between several partners: UAB; the U.S. Centers for Disease Control and Prevention (CDC) Division of HIV/AIDS Prevention and Global AIDS Program; the Centers for Infectious Disease Research in Lusaka, Zambia; the Catholic Medical Missions Board; the Lusaka Urban District Health Management Board; the University of Nairobi; Siriraj Hospital and Rajavithi Hospital in Bangkok; the Thailand Ministry of Public Health; and Northrop Grumman Corp. Funding support for the study is provided by the CDC.


Story Source:

The above story is based on materials provided by University of Alabama at Birmingham. Note: Materials may be edited for content and length.


Cite This Page:

University of Alabama at Birmingham. "HIV drug that protects a fetus should be avoided for one year after childbirth, researchers say." ScienceDaily. ScienceDaily, 28 February 2010. <www.sciencedaily.com/releases/2010/02/100225214814.htm>.
University of Alabama at Birmingham. (2010, February 28). HIV drug that protects a fetus should be avoided for one year after childbirth, researchers say. ScienceDaily. Retrieved October 20, 2014 from www.sciencedaily.com/releases/2010/02/100225214814.htm
University of Alabama at Birmingham. "HIV drug that protects a fetus should be avoided for one year after childbirth, researchers say." ScienceDaily. www.sciencedaily.com/releases/2010/02/100225214814.htm (accessed October 20, 2014).

Share This



More Health & Medicine News

Monday, October 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Microneedle Patch Promises Painless Pricks

Microneedle Patch Promises Painless Pricks

Reuters - Innovations Video Online (Oct. 18, 2014) Researchers at The National University of Singapore have invented a new microneedle patch that could offer a faster and less painful delivery of drugs such as insulin and painkillers. Video provided by Reuters
Powered by NewsLook.com
Raw: Nurse Nina Pham Arrives in Maryland

Raw: Nurse Nina Pham Arrives in Maryland

AP (Oct. 17, 2014) The first nurse to be diagnosed with Ebola at a Dallas hospital walked down the stairs of an executive jet into an ambulance at an airport in Frederick, Maryland, on Thursday. Pham will be treated at the National Institutes of Health. (Oct. 16) Video provided by AP
Powered by NewsLook.com
Raw: Cruise Ship Returns to US Over Ebola Fears

Raw: Cruise Ship Returns to US Over Ebola Fears

AP (Oct. 17, 2014) A Caribbean cruise ship carrying a Dallas health care worker who is being monitored for signs of the Ebola virus is heading back to Texas, US, after being refused permission to dock in Cozumel, Mexico. (Oct. 17) Video provided by AP
Powered by NewsLook.com
Spanish Govt: Four Suspected Ebola Cases in Spain Test Negative

Spanish Govt: Four Suspected Ebola Cases in Spain Test Negative

AFP (Oct. 17, 2014) All four suspected Ebola cases admitted to hospitals in Spain on Thursday have tested negative for the deadly virus in a first round of tests, the government said Friday. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins